ea0090p682 | Pituitary and Neuroendocrinology | ECE2023
Gadelha Monica
, Bronstein Marcello
, Grineva Elena
, Kapoor Nitin
, De Block Christophe
, Miguel Escalante Pulido Jesus
, Rollin Guilherme
, Baggenstoss Rejane
, Piacentini Andrea
, Pedroncelli Alberto
, Gallardo Wilson
Introduction: A robust clinical programme of 14 trials demonstrated pasireotide as an effective treatment for patients with rare endocrine disorders, including acromegaly and Cushings disease (CD). Patients with acromegaly or CD have significant morbidity, reduced quality of life and, if inadequately treated, higher mortality risk than the general population. This 8-year interim analysis evaluated long-term safety of pasireotide treatment in patients with acromegaly, CD ...